Authors





Omran Saifi, MD

Latest:

Radiation Therapy in Diffuse Large B-Cell Lymphoma: A Little Boost Gets You Over the Finish Line

Bradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.



MHD Louay Hasanin, MD

Latest:

Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review

Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.


Liliana Bustamante, MD

Latest:

Between the Lines™ Podcast: ctDNA as a Biomarker of Progression in Colorectal Cancer

Liliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.



Miguel Araujo-Meléndez, MD

Latest:

Disorders of Sex Development and Malignant Germ Cell Tumors

Key points: Patients with disorders of sex development (DSDs) are at an increased risk of malignant germ cell tumors (GCTs). In adulthood, the partial form of androgen insensitivity syndrome confers the greatest risk of developing malignant GCTs. Gonadoblastoma is the most common gonadal GCT arising in patients with DSDs. Despite being a benign neoplasm, it can undergo malignant transformation in up to 60% of patients with a DSD. Oncologic treatment in patients with disorders of sex development and malignant GCTs does not differ from the standard treatment for testicular GCTs. Treatment of patients with DSDs requires a multidisciplinary team, including a psychiatric, genetic, and reproductive assessment as well as the involvement of an ethics committee. An early diagnosis of DSDs is crucial to avoid the development of potentially serious complications in adulthood.


Quirin Zangl, MD

Latest:

Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary Carcinomas

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.


Christina Waters, PA-C

Latest:

Future Perspectives and Unmet Needs in Multiple Myeloma

The expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.



Harry P. Erba, MD, PhD

Latest:

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.



Kirk Harris, MD

Latest:

Oncology Peer Review On-The-Go: Cancer Pain and Opioid Use Disorder

Authors Daniel C. McFarland, DO, and Kirk Harris, MD, spoke with CancerNetwork® about their manuscript on cancer pain’s relationship with opioid use disorder that was recently published in the journal ONCOLOGY®.


Jeremy C. Jones, MD

Latest:

Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer

Investigators discuss the use of targeted therapies to treat metastatic colorectal cancer.


Abdul Baseer Wardak, MBBS

Latest:

The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion

This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.


Ashling Wahner

Latest:

Post-Transplant Daratumumab Combo Increases MRD Negativity in NDMM

Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.


Stacey Stein, MD

Latest:

A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.


Alexander Karl, MD

Latest:

Value of Geriatric Assessment in Patients With Genitourinary Carcinoma

This work from Quirin Zangl, MD, and colleagues to evaluate comprehensive geriatric assessment tools to better guide patients with urogenital carcinomas perioperatively and, consequently, to intensify or reduce hospital resource use.



Michael Foote, MD

Latest:

Future Perspectives on MRD Testing in Colorectal Cancer

The expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.


Vinay Raja, MD

Latest:

A Multidisciplinary Approach to Treating Resectable NSCLC

Surgeons, radiation oncologists, and medical oncologists gathered to discuss treatment options and approaches for NSCLC.



Paul Rodriguez, MD

Latest:

Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon Cancer

This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.



Alison J. Moskowitz, MD

Latest:

Current Treatment of Peripheral T-cell Lymphoma

This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.



Kelley Lauren Coffman, MD

Latest:

Kelley Lauren Coffman, MD, on Key Takeaways from a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs

The hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.